ZD6126

ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine. It has shown promising results on tumors in mice.
A phases of [clinical research|phase I] clinical trial identified gastrointestinal and cardiac effects as limiting dosing. Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal [cell carcinoma] and metastatic colorectal cancer.
ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent. However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.